MGMT and neoplasm: In patients with a high edema to tumor ratio, the MGMT promotor was methylated (+) in 38 patients (53%) and in 30 patients (42%) of the low edema to tumor ratio cohort (p=0.40; 95%CI: 0.36-1.37; OR: 07).